(19)
(11) EP 4 565 880 A1

(12)

(43) Date of publication:
11.06.2025 Bulletin 2025/24

(21) Application number: 23771924.0

(22) Date of filing: 04.08.2023
(51) International Patent Classification (IPC): 
G01N 33/50(2006.01)
(52) Cooperative Patent Classification (CPC):
G01N 33/502; G01N 33/5082; G01N 2333/495; G01N 2500/10; G01N 33/5061; G01N 33/5014
(86) International application number:
PCT/IB2023/000464
(87) International publication number:
WO 2024/028653 (08.02.2024 Gazette 2024/06)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
KH MA MD TN

(30) Priority: 04.08.2022 US 202263395225 P

(71) Applicant: Novoheart International Limited
Hong Kong (HK)

(72) Inventors:
  • LI, Ronald, A.
    Victoria Road Pok Fu Lam, Hong Kong (CN)
  • HAJJAR, Roger, J.
    Hong Kong (CN)

(74) Representative: Grünecker Patent- und Rechtsanwälte PartG mbB 
Leopoldstraße 4
80802 München
80802 München (DE)

   


(54) A HUMAN TISSUE MODEL FOR HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF) FOR THE DISCOVERY OF THERAPEUTICS AND THERAPEUTIC TARGETS